<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Rosa FA</submitter><funding>Fundação Araucária</funding><funding>Conselho Nacional de Desenvolvimento Científico e Tecnológico</funding><funding>Coordenação de Aperfeiçoamento de Pessoal de Nível Superior</funding><pagination>1038-1045</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10953476</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>15(3)</volume><pubmed_abstract>In this paper, we present the design and synthesis of a novel series of pyrido[2,3-&lt;i>d&lt;/i>]pyridazine-2,8-dione derivatives &lt;i>via&lt;/i> the annulation of the 2-pyridone pattern. The synthesized derivatives were evaluated for &lt;i>in vivo&lt;/i> anti-inflammatory activity using an ear edema model. Compound 7c, which showed a greater inhibition of ear edema (82%), was further tested for its &lt;i>in vitro&lt;/i> COX-1/COX-2 inhibitory activity. Compound 7c showed similar inhibitory activities against COX-1 and COX-2 isoenzymes. The structural features that ensure the dual inhibition of COX-1 and COX-2 were elucidated using molecular docking studies. Overall, the ring closing of 2-pyridone pattern I transformed this highly selective COX-2 inhibitor into a dual COX inhibitor (7c), which could serve as a </pubmed_abstract><journal>RSC medicinal chemistry</journal><pubmed_title>Discovery of a new pyrido[2,3-&lt;i>d&lt;/i>]pyridazine-2,8-dione derivative as a potential anti-inflammatory agent through COX-1/COX-2 dual inhibition.</pubmed_title><pmcid>PMC10953476</pmcid><funding_grant_id>311457/2022-3</funding_grant_id><pubmed_authors>Nakamura CV</pubmed_authors><pubmed_authors>Goncalves DS</pubmed_authors><pubmed_authors>Lazarin-Bidoia D</pubmed_authors><pubmed_authors>Bersani-Amado CA</pubmed_authors><pubmed_authors>Ames FQ</pubmed_authors><pubmed_authors>Pianoski KE</pubmed_authors><pubmed_authors>Aguiar RP</pubmed_authors><pubmed_authors>Rosa FA</pubmed_authors><pubmed_authors>Volpato H</pubmed_authors><pubmed_authors>da Silva MJV</pubmed_authors></additional><is_claimable>false</is_claimable><name>Discovery of a new pyrido[2,3-&lt;i>d&lt;/i>]pyridazine-2,8-dione derivative as a potential anti-inflammatory agent through COX-1/COX-2 dual inhibition.</name><description>In this paper, we present the design and synthesis of a novel series of pyrido[2,3-&lt;i>d&lt;/i>]pyridazine-2,8-dione derivatives &lt;i>via&lt;/i> the annulation of the 2-pyridone pattern. The synthesized derivatives were evaluated for &lt;i>in vivo&lt;/i> anti-inflammatory activity using an ear edema model. Compound 7c, which showed a greater inhibition of ear edema (82%), was further tested for its &lt;i>in vitro&lt;/i> COX-1/COX-2 inhibitory activity. Compound 7c showed similar inhibitory activities against COX-1 and COX-2 isoenzymes. The structural features that ensure the dual inhibition of COX-1 and COX-2 were elucidated using molecular docking studies. Overall, the ring closing of 2-pyridone pattern I transformed this highly selective COX-2 inhibitor into a dual COX inhibitor (7c), which could serve as a </description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Mar</publication><modification>2026-06-02T00:14:44.81Z</modification><creation>2025-04-04T02:23:00.428Z</creation></dates><accession>S-EPMC10953476</accession><cross_references><pubmed>38516591</pubmed><doi>10.1039/d3md00604b</doi></cross_references></HashMap>